Glaukos Corp (GKOS): Thomas William Burns , Chief Executive Officer of Glaukos Corp sold 24,578 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were sold at $25.16 per share for a total value of $618,382.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 3, 2016, Thomas William Burns (Chief Executive Officer) sold 422 shares at $25.00 per share price.On Jun 2, 2016, William J Phd Link (director) sold 34,058 shares at $23.98 per share price.Also, On May 5, 2016, Richard L Harrison (Treasurer, CFO & Secretary) sold 30,000 shares at $23.60 per share price.On May 5, 2016, Chris M. Calcaterra (Chief Commercial Officer) sold 74,536 shares at $23.45 per share price.
Glaukos Corp: On Friday, Jun 3, 2016 heightened volatility was witnessed in Glaukos Corp which led to swings in the share price. The shares opened for trading at $24.92 and hit $25.08 on the upside , eventually ending the session at $24.81, with a gain of 0.49% or 0.12 points. The heightened volatility saw the trading volume jump to 3,94,491 shares. The 52-week high of the share price is $33.92 and the company has a market cap of $807 M . The 52-week low of the share price is at $14.25.
Company has been under the radar of several Street Analysts.Glaukos Corp is Initiated by Cantor Fitzgerald to Buy and the brokerage firm has set the Price Target at $35. The Rating was issued on Jun 3, 2016.Glaukos Corp is Initiated by Stifel to Hold. The Rating was issued on Apr 8, 2016.
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies including three pipeline products namely the iStent Inject the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.